Don’t let siloed and unstructured data reduce the time dedicated to patient care. The SOPHiA DDM™ Platform has the capabilities of standardizing, structuring, and integrating multiomics, clinical, and biological data collected over the care journey. With access to AI-powered analytics, SOPHiA DDM™ Multimodal Healthcare Analytics amplifies clinical research by discovering novel signatures and trends, relapse and treatment response patterns without losing sight of what matters the most.

From UNSTRUCTURED PATIENT DATA to ACCURATE INSIGHTS

VISUALIZE
Harmonizing complex patient data from a longitudinal perspective

COHORT
Building research cohorts to contextualize patients within the network

PREDICT**
Uncovering trends to understand relapse & response, and guide clinical decisions

* Product in development - technology and concepts in development.
** Market availability requires approval under local regulations.
Goal: Identify predictive multimodal biomarkers associated with prognosis in non-small cell lung cancer (NSCLC) patients receiving immunotherapy.

How healthcare data analytics is amplifying clinical research

BRAIN CANCER
A recent study demonstrated that combining tumor growth rate with PFS6 improves meningioma clinical trial efficacy assessment.1

BREAST CANCER
Machine learning models have successfully identified TNBC patients at high risk of recurrence after treatment, aiding in personalizing treatment decisions.2

KIDNEY CANCER
Multimodal predictive models from clinical and imaging data helped surgeons estimate the risk of upstaging to pT3a in localized kidney cancer prior to surgery.3

DEEP-LUNG-IV
CLINICAL STUDY # NCT04994795

To date
80% predictive value 900 patients
23 participating sites 7 countries

Goal: Identify predictive multimodal biomarkers associated with prognosis in non-small cell lung cancer (NSCLC) patients receiving immunotherapy.

“I am personally very excited to join the DEEP-Lung-IV study. I see tremendous value in the multimodal machine learning-powered approach to real-world data analytics and look forward to potentially applying it to other clinical questions of high relevance in lung cancer.”

Dr. Prantesh Jain
Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center

About SOPHiA GENETICS
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine (DDM) to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare disease management, the SOPHiA™ DDM platform allows clinical researchers to act with precision and confidence. The company’s innovative approach and patented machine learning-based algorithms enable a community of more than 750 institutions to share knowledge. Together, SOPHiA GENETICS and its users are fostering a new era in healthcare.

Ready to Advance your Clinical Research?
Learn how to join our ongoing studies or explore new indications.

Get in touch →


© 2023 SOPHiA GENETICS™. All rights reserved.

These studies presents products or concepts in development. They are not products available for sale and not intended for use in diagnostic procedures or treatment decisions.